`
`~
`LUCENT IS'
`PA N ll.SlZ UMAB
`Business Use Only
`
`Lucentis PFS (RFB002)
`
`TRD SubTeam meeting
`
`Meeting Date: April 16, 2012
`Meeting Notes Date: April 23, 2012
`Author: ••••■ and team
`Room: WSJ-340.3.09
`Dial-in:
`
`Team Members:(✓ = Present, • = part-time)
`Function
`Name
`
`Team Members: (✓ = Present, * = part-time)
`Function
`
`-
`I
`I
`•
`I
`-
`-
`•
`II
`.
`-
`•
`-
`■
`•
`•
`---------(cid:173)
`■
`.
`-
`
`Executive summary
`
`I
`
`I
`I
`I
`I
`I
`
`Lucentis CMC Sub Team Meeting Minutes, Meeting Date: April 16, 2012
`
`1 of 5
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2076.001
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`Minutes
`
`Documentation
`
`I
`
`I -
`
`Lucentis CMC Sub Team Meeting Minutes, Meeting Date: April 16, 2012
`
`2 of 5
`
`CONTAINS CONFIDENTIAL BUSI NESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2076.002
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`I
`
`I
`
`I
`
`Lucentis CMC Sub Team Meeting Minutes, Meeting Date: April 16, 2012
`
`3of 5
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2076.003
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`I . - _ ;
`
`I
`
`Lucentis CMC Sub Team Meeting Minutes, Meeting Date: April 16, 2012
`
`4of 5
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2076.004
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`Action Plan
`
`What
`
`-
`
`Who
`
`When
`
`Code -
`
`Lucentis CMC Sub Team Meeting Minutes, Meeting Date: April 16, 2012
`
`5of 5
`
`CONTAINS CONFIDENTIAL BUSI NESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2076.005
`Regeneron v. Novartis, IPR2021 -00816
`
`